Trials / Recruiting
RecruitingNCT06468098
A Study of IBI363 in Subjects With Advanced Malignancies
Phase Ib Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of IBI363 Combination Therapy in Subjects With Advanced Malignancies
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 556 (estimated)
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, multicenter Phase Ib study to evaluate the safety, tolerability, and efficacy of IBI363 in advanced malignancies patients
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IBI363 + chemotherapy | In this group, patients will receive IBI363 and chemotherapy |
| DRUG | IBI363 + Investigator's Choice SOC | In this group, patients will receive IBI363 and Investigator's Choice SOC |
Timeline
- Start date
- 2024-06-15
- Primary completion
- 2025-06-30
- Completion
- 2026-12-31
- First posted
- 2024-06-21
- Last updated
- 2024-07-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06468098. Inclusion in this directory is not an endorsement.